Archive · 19 Aug 2026
Invesco India Pharma and Healthcare Fund opens NFO
Invesco Mutual Fund is offering a new investment fund focused on healthcare.
People can invest in drug companies, hospitals, testing companies and medical-device businesses.
The fund may also invest in healthcare insurance and related companies.
The offer is open until September 1.
The smallest first investment is Rs 1,000, and a monthly SIP can start at Rs 100.
Investors who leave within three months may pay a 0.50% fee.
Healthcare funds can earn good returns, but they depend heavily on one sector.
This means they can also be riskier than funds spread across many industries.
Invesco Mutual Fund’s new fund offer is open until September 1.
The fund can invest across pharmaceuticals, hospitals, diagnostics, CDMOs, CROs, medical devices and healthcare services.
Minimum investment is Rs 1,000, while SIP investments start at Rs 100.
A 0.50% exit load applies to redemptions or switches within three months of allotment.
HDFC Pharma and Healthcare Fund led one-year peer returns at 25.46%, but the category carries very high risk.
- Who
- Invesco Mutual Fund and investors in its new healthcare-focused mutual fund.
- What
- The fund house has launched the Invesco India Pharma and Healthcare Fund’s new fund offer.
- When
- The NFO is open until September 1; a 0.50% exit load applies within three months of allotment.
- Where
- The fund will invest in businesses across India’s healthcare ecosystem.
- Why
- Invesco cites rising healthcare spending, broader insurance coverage, an ageing population, lifestyle-related diseases, infrastructure expansion and healthcare innovation.
Healthcare growth opportunity
Sector-specific investment risks
Investment rationale
Healthcare growth opportunity
Invesco Mutual Fund says rising healthcare expenditure, wider insurance coverage, an ageing population, lifestyle-related diseases and expanding infrastructure could support long-term sector growth.
Sector-specific investment risks
The article notes that healthcare funds are concentrated in one sector, so their performance can be affected by regulatory changes, drug approvals, pricing policies, global demand and company valuations.
Fund selection
Healthcare growth opportunity
The fund offers flexibility to invest across the broader healthcare value chain, including established pharmaceutical companies and emerging segments such as hospitals, diagnostics, CDMOs, CROs and medical devices.
Sector-specific investment risks
Investors are cautioned not to choose a fund only because of its one-year return and should consider sector risks, valuations and longer-term consistency.
Recent performance
Healthcare growth opportunity
The top 10 pharma and healthcare schemes recorded one-year returns ranging from 19.12% to 25.46%, with newer schemes also matching established funds in the comparison.
Sector-specific investment risks
Past one-year performance does not remove the category’s stated very-high-risk profile or guarantee future results.
- NFO closing date
- September 1
- Investment scope
- Pharmaceuticals, hospitals, diagnostics, CDMOs, CROs, medical devices, healthcare services, insurance companies and related businesses
- Minimum NFO investment
- Rs 1,000
- Additional investment
- Multiples of Rs 1
- Minimum SIP
- Rs 100, in multiples of Rs 1
- Exit load
- 0.50% for redemption or switching within three months of allotment; none thereafter
- Top one-year peer return
- HDFC Pharma and Healthcare Fund: 25.46%